Neurogene Inc. unveils new data on ICV gene therapy approach at ASGCT2026

Neurogene Inc. unveils new data on ICV gene therapy approach at ASGCT2026
Neurogene Inc. at ASGCT2026

Neurogene Inc. is presenting new findings supporting the therapeutic rationale for intracerebroventricular (ICV) delivery in CNS-targeted gene therapy at the ASGCT2026 conference.

The company’s poster, numbered 1359, details encouraging preclinical data focused on this innovative approach to gene therapy within the central nervous system. Interested attendees can review the poster or access additional information via links provided by Neurogene Inc.

Neurogene previously announced plans to present on ICV delivery for CNS-targeted gene therapy at an earlier ASGCT meeting, according to a company statement. The company has also seen recent leadership changes, appointing Christy Shafer as Chief Commercial Officer and adding Christine Mikail to its board of directors, as detailed in a prior update. These developments come as Neurogene continues to pursue advances in gene therapy for CNS disorders.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.